Global pharmaceutical titan GSK plc is teaming up with Chongqing Zhifei Biological Products, Ltd. (Zhifei) – China’s leading vaccine revenue generator – to co-promote its groundbreaking shingles vaccine, Shingrix, across the vast Chinese terrain. This exclusive three-year collaboration, beginning 1 January 2024, is set to be a game-changer in elevating patient access to Shingrix. There’s […]
GSK has agreed to acquire BELLUS Health, a Canadian biopharma company, in a deal worth around $2 billion in a move to further bolster its specialty medicines and respiratory pipeline. The deal gives GSK access to a late-stage P2X3 antagonist called camlipixant, which is intended for the treatment of refractory chronic cough (RCC). Presently, camlipixant […]
GlaxoSmithKline (GSK) has agreed to acquire Sierra Oncology, a California-based biopharma company, in a deal worth around $1.9 billion (£1.5 billion). As per the terms of the deal, shareholders of the publicly-listed Sierra Oncology will be paid $55 per share in cash. Sierra Oncology is engaged in developing targeted therapies for the treatment of rare […]